Addinex will work with Yale School of Medicine, Aware Recovery Care and the In-Home Addiction Treatment Institute to customize its award-winning opioid delivery system

NEW YORK – September 7, 2022 – (Newswire.com)

Addinex Technologies, Inc., a health technology company focused on drug delivery innovation, has received a $260,000 grant from the Centers for Disease Control and Prevention (CDC) for Phase I Small Business Innovation Research (SBIR ) received to improve existing addiction drug delivery for people with opioid use disorder (OUD).

The grant will help fund the adaptation of Addinex’s award-winning patented pill delivery system, which recently completed a successful study of opioids in postoperative cancer patients at Columbia University Medical Center. The results of this study were recently published in the peer review journal. Cancer. The customized dispenser works with buprenorphine, including Suboxone^®a common form of addiction treatment medication available in a sublingual film, and Addinex’s patient app will focus on the unique needs of people suffering from OUD.

“9.5 million people aged 12 and over abuse opioids, accounting for 3.3% of this population, 2.7 million people suffer from OUD, and annual opioid overdose deaths have recently exceeded 80,000. Many patients diagnosed with OUD are treated with a combination of buprenorphine, a Schedule III narcotic, along with counseling and behavioral therapies, also known as drug-assisted treatment,” he explained Jay Schiff, Co-Founder and CEO of Addinex Technologies, Inc. “Our patented, low-cost medication delivery system offers a cost-effective way to improve adherence and reduce distractions while educating patients on proper use and facilitating disposal of excess medication. We are pleased to partner with a world-class team of addiction treatment providers and researchers.”

“I am very excited about this research project and the extraordinary…